Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study | Zendy

Payal Kohli | Zendy; Lars Wallentin | Zendy; Eric Reyes | Zendy; Jay Horrow | Zendy; Steen Husted | Zendy; Dominick J. Angiolillo | Zendy; Diego Ardissino | Zendy; Gerald Maurer | Zendy; João Morais | Zendy; José Carlos Nicolau | Zendy; Ali Oto | Zendy; Robert F. Storey | Zendy; Stefan James | Zendy; Christopher P. Can | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study

Author(s) -

Payal Kohli,

Lars Wallentin,

Eric Reyes,

Jay Horrow,

Steen Husted,

Dominick J. Angiolillo,

Diego Ardissino,

Gerald Maurer,

João Morais,

José Carlos Nicolau,

Ali Oto,

Robert F. Storey,

Stefan James,

Christopher P. Can

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.124248

Subject(s) - ticagrelor , medicine , hazard ratio , cardiology , myocardial infarction , clopidogrel , acute coronary syndrome , stroke (engine) , proportional hazards model , confidence interval , mechanical engineering , engineering

We sought to evaluate the effect of potent platelet inhibition after acute coronary syndrome on total (ie, first and recurrent) occurrences of any of the primary outcome events (e.g., cardiovascular death, myocardial infarction, and stroke) as well as on other ischemic events, such as urgent revascularization, (severe) recurrent ischemia, transient ischemic attacks, and arterial thrombotic events.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research